A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission

Arthritis, Rheumatoid Clinical Trial

— ADMIRE  

Official title:

A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission (ADMIRE)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00808509
• Other study ID #: W10-046
• Secondary ID: 2008-004398-16
• Status: Completed
• Phase: Phase 4
• First received: December 12, 2008
• Last updated: November 21, 2013
• Start date: January 2009
• Est. completion date: September 2012

Study information

• Verified date: November 2013
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Health authority: Sweden: Medical Products Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this pilot study is to investigate the possibility of discontinuing adalimumab therapy in patients with rheumatoid arthritis who are in stable remission after treatment with adalimumab in combination with methotrexate.

Description:

Treatments with adalimumab and other tumor necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), are usually continued indefinitely. Information concerning the possibility of discontinuing anti-TNF therapy in RA patients who are in remission is limited. This is a pilot study in one country to study the effect of adalimumab discontinuation. The objective is to assess the proportion of patients with established RA in stable remission (Disease Activity Score [DAS]28 <2.6) after treatment with adalimumab in combination with methotrexate, in whom it is possible to discontinue adalimumab and to compare the remission rates among patients on sustained therapy with adalimumab + methotrexate with remission rates among patients who discontinued adalimumab.

Rheumatoid arthritis patients in stable remission (DAS28 < 2.6) treated with adalimumab + methotrexate were randomized in a 1:1 ratio to continue with adalimumab treatment or discontinue adalimumab treatment for the following 52 weeks. Subsequently an observational extension was conducted to observe patients treated at the discretion of the investigator. The observational extension period lasted until Weeks 105 - 156 (average Week 125) and consisted of one follow-up visit. Participants randomized to discontinue adalimumab therapy will be reinstituted to adalimumab if DAS28-score increases by >1.2 units from baseline and/or is scored ≥2.6 at any visit during the study and will be followed for an additional 12 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: September 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18 years.

• Diagnosis of RA as defined by the 1987-revised American College of Rheumatology (ACR)-classification and has positive rheumatoid factor (RF) test or erosion on X-ray of hands or feet.

• Currently treated with adalimumab and MTX (at least 10 mg/week; orally or subcutaneously).

• In remission as defined by disease activity score (DAS)28 <2.6 for at least the past 3 months.

• Concomitant disease-modifying anti-rheumatic drug (DMARD) or oral corticosteroid therapy has been stable for at least 3 months at study entry.

• Female subject is either not of childbearing potential or is practicing a relevant method of birth control.

• Subject is judged to be in good general health.

• Subjects must be able and willing to provide written informed consent.

• Subjects must be able and willing to self-administer subcutaneous (SC) injections or have a qualified person available to administer SC injections.

Exclusion Criteria:

• Treatment with intra-articular or parenteral administration of corticosteroids in the preceding 4 weeks.

• Oral prednisone or prednisone equivalent > 10 mg/day at baseline.

• Joint surgery within the preceding two months.

• History of acute inflammatory joint disease other than RA.

• Treatment with any investigational drug within 30 days or 5 half lives, whichever is longer prior to study entry.

• Poorly controlled medical condition, which would put the subject at risk by participation in the study.

• History of clinically significant hematologic, renal or liver disease.

• Diagnosis of, or history suggestive of, central nervous system (CNS) demyelinating disease.

• History of cancer or lymphoproliferative disease other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma of the cervix.

• History of listeriosis, histoplasmosis, untreated tuberculosis (TB), persistent chronic infections, or recent active infections.

• Known immune deficiency or human immunodeficiency virus (HIV).

• Female who is pregnant or breast-feeding or considering becoming pregnant or breast feeding during the study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid

Intervention

Biological:
• adalimumab
40 mg every other week via subcutaneous injection

Drug:
• methotrexate
At least 10 mg/week administered orally or subcutaneously

Locations

Country	Name	City	State
Sweden	Site Reference ID/Investigator# 22062	Linkoping
Sweden	Site Reference ID/Investigator# 14022	Lund
Sweden	Site Reference ID/Investigator# 14023	Malmo
Sweden	Site Reference ID/Investigator# 14301	Oskarstroem
Sweden	Site Reference ID/Investigator# 20241	Skoevde
Sweden	Site Reference ID/Investigator# 14021	Stockholm
Sweden	Site Reference ID/Investigator# 4918	Stockholm
Sweden	Site Reference ID/Investigator# 14302	Uppsala

Sponsors (2)

Lead Sponsor	Collaborator
AbbVie (prior sponsor, Abbott)	Pharma Consulting Group AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants in Remission at Week 28	Remission is defined as a Disease Activity Score (DAS)28 of less than 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.; In this analysis participants in the methotrexate treatment group with a DAS28 score = 2.6 (and thus allocated to rescue therapy with adalimumab) prior to Week 28 were considered not to be in remission at Week 28. Also, participants who did not complete 28 weeks were considered not in remission.	Week 28	No
Primary	Percentage of Participants in Remission at Week 28 in the Full Analysis Set 2 (FAS2)	Remission is defined as a Disease Activity Score (DAS)28 of less than 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.; In this analysis participants in the methotrexate treatment group with a DAS28 score = 2.6 (and thus allocated to rescue therapy with adalimumab) prior to Week 28 were considered not to be in remission at Week 28. Also, participants who did not complete 28 weeks were considered not in remission.	Week 28	No
Secondary	Percentage of Participants in Remission at Week 52	Remission is defined as a Disease Activity Score (DAS)28 of less than 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.; In this analysis participants in the methotrexate treatment group with a DAS28 score = 2.6 (and thus allocated to rescue therapy with adalimumab) prior to Week 52 were considered not to be in remission at Week 52. Also, participants who did not complete 52 weeks were considered not in remission.	Week 52	No
Secondary	Percentage of Participants in Remission at Week 52 (FAS2)	Remission is defined as a Disease Activity Score (DAS)28 of less than 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity. Also, participants who did not complete 52 weeks were considered not in remission.; In this analysis participants in the methotrexate treatment group with a DAS28 score = 2.6 (and thus allocated to rescue therapy with adalimumab) prior to Week 52 were considered not to be in remission at Week 52.	Week 52	No
Secondary	Number of Participants With a Flare	Flare is defined as DAS28 =2.6 or an increase from Baseline in the DAS28 of greater than 1.2 units. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.	Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, and 52	No
Secondary	Percentage of Participants With Response to Adalimumab Treatment (Return to Baseline DAS28 + = 10%) After a Flare	For participants with a flare and treated with adalimumab rescue therapy, response was defined as return to Baseline DAS28 + = 10% after reinstitution of adalimumab (rescue therapy).; The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.	1 to 4 weeks, 5 to 8 weeks, 9 to 12 weeks, and 13 to 16 weeks after reinstitution of adalimumab rescue therapy	No
Secondary	Percentage of Participants With Response to Adalimumab Treatment (DAS28 <2.6 or DAS28 Decrease >1.2 Units) After a Flare	For participants with a flare and treated with adalimumab rescue therapy, response was defined as DAS28 less than 2.6 or DAS28 decrease of greater than 1.2 units after reinstitution of adalimumab (rescue therapy). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.	1 to 4 weeks, 5 to 8 weeks, 9 to 12 weeks, and 13 to 16 weeks after reinstitution of adalimumab rescue therapy	No
Secondary	Health Assessment Questionnaire (HAQ) Total Score by Visit	Physical function was evaluated using the Health Assessment Questionnaire - Disability Index (HAQ-DI), a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI < 0.5.	Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)	No
Secondary	European Quality of Life-5 Dimensions (EQ-5D) Mobility Score by Visit	The EQ-5D is an international, standardized, generic instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their mobility health state: Level 1: I have no problems in walking about; Level 2: I have some problems in walking about; Level 3: I am confined to bed.	Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)	No
Secondary	European Quality of Life-5 Dimensions (EQ-5D) Self-care Score by Visit	The EQ-5D is an international, standardized, generic instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their self-care health state: Level 1: I have no problems with self-care; Level 2: I have some problems washing or dressing myself; Level 3: I am unable to wash or dress myself.	Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)	No
Secondary	European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score by Visit	The EQ-5D is an international, standardized, generic instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state with regard to usual activities (work, study, housework, family, or leisure activities): Level 1: I have no problems performing my usual activities; Level 2: I have some problems performing my usual activities; Level 3: I am unable to perform my usual activities.	Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)	No
Secondary	European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score by Visit	The EQ-5D is an international, standardized, generic instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their pain/discomfort health state: Level 1: I have no pain or discomfort; Level 2: I have moderate pain or discomfort; Level 3: I have extreme pain or discomfort.	Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)	No
Secondary	European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score by Visit	The EQ-5D is an international, standardized, generic instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their anxiety/depression health state: Level 1: I am not anxious or depressed; Level 2: I am moderately anxious or depressed; Level 3: I am extremely anxious or depressed.	Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)	No
Secondary	European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) by Visit	The EQ-5D is an international, standardized, generic instrument for describing and evaluating health status. Health status is assessed by patients evaluating their health on a vertical, visual analog scale from 0 to 100 where the endpoints are labeled 'Worst imaginable health state' (0) and 'Best imaginable health state' (100).	Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)	No
Secondary	Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale by Visit	The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions on a scale from 'not at all' (0) to 'very much' (4). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue.	Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)	No
Secondary	Work Instability Score (WIS) for RA: I'm Getting up Earlier Because of Arthritis	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 1, participants selected either Yes or No if the following statement currently applied to them or not: I'm getting up earlier because of the arthritis.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I Get Very Stiff at Work	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 2, participants selected either Yes or No if the following statement currently applied to them or not: I get very stiff at work.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I'm Finding my Job is About All I Can Manage	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 3, participants selected either Yes or No if the following statement currently applied to them or not: I'm finding my job is about all I can manage.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: The Stress of my Job Makes my Arthritis Flare	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 4, participants selected either Yes or No if the following statement currently applied to them or not: The stress of my job makes my arthritis flare.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I'm Finding Any Pressure on my Hands is a Problem	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 5, participants selected either Yes or No if the following statement currently applied to them or not: I'm finding any pressure on my hands is a problem.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I Get Good Days and Bad Days at Work	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 6, participants selected either Yes or No if the following statement currently applied to them or not: I get good days and bad days at work.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I Can Get my Job Done, I'm Just a Lot Slower	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 7, participants selected either Yes or No if the following statement currently applied to them or not: I can get my job done, I'm just a lot slower.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: If I Don't Reduce my Hours I May Have to Give up Work	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 8, participants selected either Yes or No if the following statement currently applied to them or not: If I don't reduce my hours I may have to give up work.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I am Very Worried About my Ability to Keep Working	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 9, participants selected either Yes or No if the following statement currently applies to them or not: I am very worried about my ability to keep working.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I Have Pain or Stiffness All the Time at Work	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 10, participants selected either Yes or No if the following statement currently applies to them or not: I have pain or stiffness all the time at work.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I Don't Have the Stamina to Work Like I Used to	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 11, participants selected either Yes or No if the following statement currently applies to them or not: I don't have the stamina to work like I used to.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I Have Used my Vacation so That I Don't Have to Take Sick Leave	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 12, participants selected either Yes or No if the following statement currently applies to them or not: I have used my vacation so that I don't have to take sick leave.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I Push Myself to go to Work Because I Don't Want to Give in to the Arthritis	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 13, participants selected either Yes or No if the following statement currently applies to them or not: I push myself to go to work because I don't want to give in to the arthritis.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: Sometimes I Can't Face Being at Work All Day	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 14, participants selected either Yes or No if the following statement currently applies to them or not: Sometimes I can't face being at work all day.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I Have to Say No to Certain Things at Work	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 15, participants selected either Yes or No if the following statement currently applies to them or not: I have to say no to certain things at work.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I've Got to Watch How Much I do Certain Things at Work	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 16, participants selected either Yes or No if the following statement currently applies to them or not: I've got to watch how much I do certain things at work.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I Have Great Difficulty Opening Some of the Doors at Work	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 17, participants selected either Yes or No if the following statement currently applies to them or not: I have great difficulty opening some of the doors at work.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I Have to Allow Myself Extra Time to do Some Jobs	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 18, participants selected either Yes or No if the following statement currently applies to them or not: I have to allow myself extra time to do some jobs.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: It's Very Frustrating Because I Can't Always do Things at Work	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 19, participants selected either Yes or No if the following statement currently applies to them or not: It's very frustrating because I can't always do things at work.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I Feel I May Have to Give up Work	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 20, participants selected either Yes or No if the following statement currently applies to them or not: I feel I may have to give up work.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I Get on With the Work But Afterwards I Have a Lot of Pain	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 21, participants selected either Yes or No if the following statement currently applies to them or not: I get on with the work but afterwards I have a lot of pain.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: When I'm Feeling Tired All the Time Work is a Grind	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 22, participants selected either Yes or No if the following statement currently applies to them or not: When I'm feeling tired all the time work is a grind.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Instability Score (WIS) for RA: I'd Like Another Job But I am Restricted to What I Can do	Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 23, participants selected either Yes or No if the following statement currently applied to them or not: I'd like another job but I am restricted to what I can do.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Productivity and Activity Impairment (WPAI): Currently Employed	The Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) questionnaire was used to assess work and activity impairment due to symptoms of rheumatoid arthritis in the last 7 days. The self-administered questionnaire consists of 6 questions. Question 1 asks participants to indicate if they are currently employed or working for pay (Yes or No).	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Productivity and Activity Impairment (WPAI): Hours Missed From Work	The Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) questionnaire was used to assess work and activity impairment due to symptoms of rheumatoid arthritis in the last 7 days. The self-administered questionnaire consists of 6 questions. Question 2 asks participants who are employed or working for pay to indicate the number of hours missed from work due to problems associated with their rheumatoid arthritis.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Productivity and Activity Impairment (WPAI): Hours Missed From Work for Other Reasons	The Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) questionnaire was used to assess work and activity impairment due to symptoms of rheumatoid arthritis in the last 7 days. The self-administered questionnaire consists of 6 questions. Question 3 asks participants who are employed or working for pay to indicate the number of hours missed from work due to reasons other than rheumatoid arthritis.	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Productivity and Activity Impairment (WPAI): Hours Worked	The Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) questionnaire was used to assess work and activity impairment due to symptoms of rheumatoid arthritis in the last 7 days. The self-administered questionnaire consists of 6 questions. Question 4 asks participants who are employed or working for pay to indicate the number of hours actually worked during the past 7 days.	Baseline and at Weeks 12, 28, 52 and 104-156	No
Secondary	Work Productivity and Activity Impairment (WPAI): Work Productivity	The Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) questionnaire was used to assess work and activity impairment due to symptoms of rheumatoid arthritis in the last 7 days. The self-administered questionnaire consists of 6 questions. Question 5 asks participants who are employed or working for pay to indicate how much their rheumatoid arthritis impaired their productivity while working in the past 7 days on a scale from 0 (no effect) to 10 (completely prevented from working).	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Work Productivity and Activity Impairment (WPAI): Daily Activities	The Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) questionnaire was used to assess work and activity impairment due to symptoms of rheumatoid arthritis in the last 7 days. The self-administered questionnaire consists of 6 questions. Question 6 asks participants to indicate how much their rheumatoid arthritis affected their ability to do their regular daily activities such as housework, childcare, exercising, shopping, studying, etc, in the past 7 days on a scale from 0 (no effect) to 10 (completely prevented from doing daily activities).	Baseline and at Weeks 12, 28, 52, and 104-156	No
Secondary	Change From Baseline in Radiological Modified Total Sharp Score	The van der Heijde modified Total Sharp Score (mTSS) is a measure of the level of joint damage. X-rays of hands and feet were taken at Baseline, Week 52 and the Week 104-156 visit. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.	Baseline, Week 52, and Weeks 104-156	No

External Links

•   Link